Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/42750
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKoollawat Chupraditen_US
dc.contributor.authorSutpirat Moonmuangen_US
dc.contributor.authorSawitree Nangolaen_US
dc.contributor.authorKuntida Kitideeen_US
dc.contributor.authorUmpa Yasamuten_US
dc.contributor.authorMarylène Mougelen_US
dc.contributor.authorChatchai Tayapiwatanaen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherUniversité de Montpellieren_US
dc.contributor.otherUniversity of Phayaoen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-21T07:52:53Z
dc.date.accessioned2019-03-14T08:03:46Z-
dc.date.available2018-12-21T07:52:53Z
dc.date.available2019-03-14T08:03:46Z-
dc.date.issued2017-10-01en_US
dc.identifier.citationViruses. Vol.9, No.10 (2017)en_US
dc.identifier.issn19994915en_US
dc.identifier.other2-s2.0-85030563444en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85030563444&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/42750-
dc.description.abstract© 2017 by the authors.Licensee MDPI, Basel, Switzerland. Human immunodeficiency virus (HIV) is a causative agent of acquired immune deficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) can slow down the replication of HIV-1, leading to an improvement in the survival of HIV-1-infected patients. However, drug toxicities and poor drug administration has led to the emergence of a drug-resistant strain. HIV-1 immunotherapy has been continuously developed, but antibody therapy and HIV vaccines take time to improve its efficiency and have limitations. HIV-1-specific chimeric antigen receptor (CAR)- based immunotherapy founded on neutralizing antibodies is now being developed. In HIV-1 therapy, anti-HIV chimeric antigen receptors showed promising data in the suppression of HIV-1 replication; however, autologous transfusion is still a problem. This has led to the development of effective peptides and proteins for an alternative HIV-1 treatment. In this paper, we provide a comprehensive review of potent anti-HIV-1 peptides and proteins that reveal promising therapeutic activities. The inhibitory mechanisms of each therapeutic molecule in the different stages of the HIV- 1 life cycle will be discussed herein.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85030563444&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.titleCurrent peptide and protein candidates challenging HIV therapy beyond the vaccine Eraen_US
dc.typeReviewen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.3390/v9100281en_US
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.